$0.62

-0.02 (-3.14%)

9/5/2008 3:59 PM

Hemispherx BioPharma, Inc. (HEB)

CAPS Rating:

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

HEB doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

33 Outperforms

53 Underperforms

All-Stars

4 Outperforms

29 Underperforms

Wall Street

1 Outperforms

0 Underperforms

Members bullish on HEB are also bullish on:

Members bearish on HEB are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (294)
Suggest a tag

Hemispherx BioPharma, Inc. At A Glance

Current Price:	$0.62
Last Trade Time:	9/5/2008 3:59 PM
Open:	$0.64
Previous Close:	$0.64
Daily Range:	$0.62 - $0.66
52-Week Range:	$0.53 - $2.08
Volume:	63,424
Market Cap:	$47.97M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

HEB VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for HEB

Hemispherx Rises on HIV/avian Flu Plans
4/7/2008 5:16:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 Hemispherx BioPharma, Inc. (HEB)

Avatar domsheldon (< 20) Submitted: 10/03/07 5:28 PM

Double blind placebo controlled phase 3 trial.
Disease: chronic fatigue syndrome.
Market: 1 to 3 million patients in the US.
Data is good. They achieved statistical significance with the primary endpoint and no significant side effects were noticed.
This happened 3 years ago.More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1 Hemispherx BioPharma, Inc. (HEB)

Avatar Allstar13913 (99.92) Submitted: 2/21/07 7:06 PM

Bill Mann said it best. This stock is crap. Ampligen their

Replies: 0 | Reply | Permalink

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 19 : 1 2 3 4 Next »

Show Pitch Replies

Recs 0 (HEB) artisan99 (40.97) Submitted: 10/26/07 12:36 AM : Start Price: $1.85 HEB Score: -47.77 If the data shows that Ampligen help CFS then this could be the story that pushes HEB much higher. However, one stock that is too small to put on this site is Nanoviricides NNVC and it will far outperform HEB in the 2 - 4 year time frame for anti-virus vaccines especially bird flu, Hep C, Rabies and even HIV Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (HEB) Calpe32D (< 20) Submitted: 10/25/07 1:21 PM : Start Price: $1.59 HEB Score: -43.82 Afther FDA-approval Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (HEB) rallypoint10 (< 20) Submitted: 10/12/07 12:46 PM : Start Price: $1.88 HEB Score: -46.74 Finally achieving commercial viability with their recent filing of a new drug application for Ampligen, to treat Chronic Fatigue Syndrome. Other applications for the proprietary, RNA-based biotechnology. Revenues are still a ways out, but should begin to appreciate with market acceptance of new drugs. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (HEB) cfsguy99 (< 20) Submitted: 10/11/07 2:01 PM : Start Price: $1.77 HEB Score: -44.46 HemispherX Biopharma is the ONLY drug company to develop and fully test a treatment drug for the disabling, devastating illness with the silly name: "Chronic Fatigue Syndrome (Myalgic Encephalomyllitus or M.E.)" I know just how devasting this illness is, as I am disabled by iit. Today, HEB has submitted a new drug application (NDA) to the FDA for approval. HEB owns dozens of worldwide patents on "AMPLIGEN". It might still be considered specualtive since the FDA has yet to approve the drug, however, as a person with CFS/ME who participated in the drug trials...I know it helps. It will help the majority of the 1-2 million people sufffering from this illness in the US alone. AND it may have helpful immune system benefit for other diverse conditions such as bird flu, AIDS and even toxic chemical exposure. Report this Post Replies: 2 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (HEB) CalmVoice (< 20) Submitted: 10/04/07 4:28 PM : Start Price: $1.65 HEB Score: -42.68 Its products are versatile. They appear effective in their own right and they also appear to boost the power of a range of other medicines. Hemispherx is also forming partnerships with other companies that wish to take advantage of its products, making it likely that they will have an increasingly growing revenue stream. Report this Post Replies: 1 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 19 : 1 2 3 4 Next »

Wall Street

Results 1 - 1 of 1

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackBoenning	23.04	12/05/06		NS	$2.15	-71.16%	-11.33%	-59.84

Results 1 - 1 of 1

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

HEB Score Leader

LurkyLurky
Rating: 99.98
HEB Score: 97.17

I hope that Bill Mann (TMFOtter) won't mind me quoting him: "I've made a lot of money shorting Hemispherx over time, just wait for the next big pump and do it all over again."